Article Text

Download PDFPDF
Review: differences in efficacy and acceptability exist for 12 new-generation antidepressants for major depression

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


What is the relative efficacy of 12 new-generation antidepressants for relieving major depression?

Review scope

Included studies were randomised controlled trials (RCTs) that compared any of 12 new-generation antidepressants (bupropion, citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnaciprin, mirtazapine, paroxetine, reboxetine, sertraline, and venlafaxine) as monotherapy for acute-phase treatment of major depression. Placebo groups and RCTs of postpartum depression were excluded. Outcomes were response and dropout rates at 8 weeks.

Review methods

Cochrane Collaboration Depression, Anxiety, and Neurosis Review Group’s controlled trials register (to Nov 2007) and reference lists were searched for RCTs. Pharmaceutical companies, regulatory agencies, and study investigators were contacted. 117 RCTs (n = 25 928; 64% women; 53 RCTs [n = 9321] had patients >65 y of age) were included. Mean …

View Full Text


  • Source of funding: no external funding.